HB3672, titled the Securities Research Modernization Act, amends the Securities Act of 1933 to broaden the “research report” exception. Under current law, the exception is tied to research reports about an emerging growth company in connection with certain public offerings; this bill replaces that narrower reference with “an issuer,” expands the covered securities from “the common equity” to “any” securities, and updates related language accordingly. The practical effect is to allow research reports to be published in connection with proposed offerings by a wider range of issuers, not just emerging growth companies.
The bill is a targeted securities-market change focused on capital formation and analyst research. By modernizing the research report exception, it aims to reduce restrictions on the distribution of investment research around public offerings, potentially improving market information flow and making it easier for issuers to attract investor attention during offerings. The bill does not create a new regulatory regime; rather, it amends a specific provision of the Securities Act of 1933 that governs when research reports may be provided without triggering offering-related restrictions.
The available record shows no committee transcript, no recorded votes, and no stated opposition or support in the provided materials. As a result, the general sentiment cannot be measured from debate or floor action, though the bill’s reported status suggests it received enough committee support to advance with an amendment. The absence of recorded contention in the supplied context means there is no documented dispute here over the bill’s scope, but the main policy issue inherent in the measure is the balance between facilitating analyst research and preserving investor-protection safeguards during securities offerings.
In terms of legal impact, the bill would amend Section 2(a)(3) of the Securities Act of 1933 by substituting broader issuer-based language for the existing emerging-growth-company limitation. That change would affect issuers undertaking proposed public securities offerings, broker-dealers, analysts, and underwriters by expanding when research reports may be distributed without violating offering communications rules. The bill is therefore a securities-law modernization measure aimed at broadening permissible market research in the public offering context.
Impact
HB3672 would amend Section 2(a)(3) of the Securities Act of 1933 to expand the research report exception from emerging growth companies to any issuer undertaking a proposed offering of public securities, and to cover any securities rather than only common equity. This would affect issuers, broker-dealers, analysts, and underwriters by broadening the circumstances in which research reports can be published or distributed around securities offerings, while leaving the broader securities registration and antifraud framework intact.
Sentiment
Based on the provided record, the bill appears to have moved forward without recorded floor debate or votes, and it was reported with an amendment by the House Committee on Financial Services. That suggests at least procedural support in committee, but there is no transcript evidence of broader public sentiment. Overall, the measure appears to be a technical, pro-market securities modernization bill rather than a highly controversial proposal.
Contention
No specific points of contention are documented in the supplied materials because there are no committee transcripts or recorded votes. The underlying policy tension, however, is between expanding access to research reports to support capital formation and maintaining limits designed to prevent conflicted or premature promotional communications during public offerings. Any disagreement would likely center on whether extending the exception to all issuers and all securities could weaken investor-protection safeguards.
Securing American Funding and Expertise from Adversarial Research Exploitation Act of 2025 Anti-CBDC Surveillance State Act Coast Guard Authorization Act of 2025 SAFE Research Act